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Abstract
Introduction: Diffuse intrinsic pontine glioma (DIPG) is a malignant pediatric brain tumor associated with dismal
outcome. Recent high-throughput molecular studies have shown a high frequency of mutations in histone-
encoding genes (H3F3A and HIST1B) and distinctive epigenetic alterations in these tumors. Epigenetic alterations
described in DIPG include global DNA hypomethylation. In addition to the generally repressive methylcytosine DNA
alteration, 5-hydroxymethylation of cytosine (5hmC) is recognized as an epigenetic mark associated with active
chromatin. We hypothesized that in addition to alterations in DNA methylation, that there would be changes in
5hmC. To test this hypothesis, we performed immunohistochemical studies to compare epigenetic alterations in
DIPG to extrapontine adult and pediatric glioblastoma (GBM) and normal brain. A total of 124 tumors were scored
for histone 3 lysine 27 trimethylation (H3K27me3) and histone 3 lysine 9 trimethylation (H3K9me3) and 104 for
5hmC and 5-methylcytosine (5mC). An H-score was derived by multiplying intensity (0–2) by percentage of positive
tumor nuclei (0-100%).
Results: We identified decreased H3K27me3 in the DIPG cohort compared to pediatric GBM (p < 0.01), adult GBM
(p < 0.0001) and normal brain (p < 0.0001). H3K9me3 was not significantly different between tumor types. Global
DNA methylation as measured by 5mC levels were significantly lower in DIPG compared to pediatric GBM (p < 0.001),
adult GBM (p < 0.01), and normal brain (p < 0.01). Conversely, 5hmC levels were significantly higher in DIPG compared
to pediatric GBM (p < 0.0001) and adult GBM (p < 0.0001). Additionally, in an independent set of DIPG tumor samples,
TET1 and TET3 mRNAs were found to be overexpressed relative to matched normal brain.
Conclusions: Our findings extend the immunohistochemical study of epigenetic alterations in archival tissue to DIPG
specimens. Low H3K27me3, decreased 5mC and increased 5hmC are characteristic of DIPG in comparison with
extrapontine GBM. In DIPG, the relative imbalance of 5mC compared to 5hmC may represent an opportunity for
therapeutic intervention.
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Introduction
Tumors of the central nervous system are the second most
common malignancy in pediatric patients. Diffuse intrinsic
pontine gliomas (DIPGs) comprise approximately 10% of
pediatric brain tumors and are universally fatal [1]. Due to
their location, DIPGs have rarely been biopsied at diagno-
sis outside of recent clinical trials. No improvements in
DIPG outcome have been noted in the past 20 years, per-
haps due to the paucity of patient-derived samples and
lack of molecular insights leading to novel treatments.
Encouragingly, recent molecular and proteomic analyses
of autopsy specimens have identified key genetic alter-
ations in DIPG, including amplifications in genes en-
coding receptor tyrosine kinases (PDGFRA, MET) [2],
PDGFRA mutations [3], as well as distinct DIPG sub-
groups based on Hedgehog (SHH) and MYCN pathway
activation [4]. Mutations in the ACVR1 gene, encoding
the transforming growth factor-beta (TGF-beta) super-
family member activin, have been reported in approxi-
mately 20% of DIPGs [5,6].
Epigenetic research has added to our understanding of
how chromatin remodeling by methylation and acetylation
of histones affects gene expression in tumors [7]. Among
brain tumors, glioblastomas (GBMs) can be subdivided
into 6 groups based on DNA methylation patterns. DIPGs
are classified within one group that has relatively hypo-
methylated DNA and are associated with mutations in
genes encoding for histone proteins [8-11]. Approximately
60% of DIPGs have a mutation in the H3F3A gene which
encodes the variant histone 3.3 proteins [11], which is also
associated with a worse prognosis [12]. Less frequently,
DIPGs have mutations in HIST1H3B, encoding for histone
H3.1, while other extrapontine pediatric high-grade gli-
omas may have alternative mutations in H3F3A (G34R or
G34V) [13,8,9]. As a result of the common missense mu-
tation (H3F3A), lysine at position 27 (H3K27) is changed
to methionine (K27M) in the amino terminal tail of his-
tone 3.3 [10]. Post-translational modification of this
critical histone regulates gene expression, DNA repair,
and maintenance of centromeres/telomeres [8]. Methy-
lation of the H3K27 is mediated by polycomb repressive
complex 2 (PRC2), which binds to polycomb group (PcG)
target genes and induces the PRC2 component enhancer
of zeste homologue 2 (EZH2) methyltransferase to methy-
late H3K27. Histone methylation creates a repressed state
by inhibiting transcription, altering chromatin compac-
tion, and affecting recruitment of DNA methyltransferases
(DNMTs) [8,14]. The H3K27M mutant histone inhibits
PRC2 by interacting with EZH2 and suppressing its func-
tion [13]. Therefore, as a result of the K27M mutation,
histone methylation is decreased at this site [8,9,13,10].
H3.3 is primarily found at transcription sites and telo-
meres, and the H3K27M mutant H3.3 is associated with
transcriptionally active (open) chromatin [8]. Inhibition of
histone K27 tri-methylation (H3K27me3) leads to global
activation of transcription [8,13].
One of the most studied epigenetic alterations is
methylation of DNA. Mammalian DNA methylation oc-
curs primarily at the 5-position of cytosines (5mC) in
CpG dinucleotides. Methylated cytosines at gene pro-
moters with high GC content (CpG islands) are usually
associated with transcriptional silencing. Loss of 5mC
leads to a redistribution of PRC2 complexes which suggests
that 5mC could affect interactions between PRC2 and chro-
matin [15]. Aberrant recruitment of PRC2 to DNA not
usually associated with H3K27me3 may shift PRC2 away
from original targets and again promote an active transcrip-
tional state. H3K27me3 is not uniformly increased in
these hypomethylated DNA regions, which provides evi-
dence that DNA methylation is one of many epigenetic
factors affecting PRC2 function [15,10]. A hypomethy-
lated genome, in addition to the H3F3A mutation, likely
accentuates the transcriptionally active state of DIPGs
by disrupting histone methylation at H3K27me3.
The methylation of cytosine in CpG islands is a modi-
fication produced by DNMTs. Reversal of 5mC methyla-
tion is accomplished in a multistep enzymatic process
using Ten Eleven Translocation (TET) enzymes, thy-
mine DNA glycosylase (TDG), and base excision repair
(BER) [16,17]. TET enzymes can convert 5mC in a re-
action dependent on alpha-ketoglutarate (α-KG) to 5-
hydroxymethylcytosine (5hmC) [16,18]. 5hmC can then
either be further processed by TDG and BER or persist as
5hmC in mammalian genomes [19]. Decreased 5hmC
levels have been described in a variety of cancers [20], as
well as in high-grade gliomas [21]. 5hmC is often associ-
ated with the gene bodies of actively transcribed genes
and is considered an epigenetic mark in its own right [17].
These studies raise the possibility that unregulated loss
of H3K27me3 through H3K27M mutation and elevated
5hmC could shift normal development into a pathologic
state. The association between loss of H3K27me3 and ele-
vated 5hmC in neural development also suggests a regula-
tory cross talk between these two pathways. Histone 3
lysine 9 methylation (H3K9me3) is another important his-
tone methylation mark implicated in the development of
gliomas. Methylation at this site affects global DNA methy-
lation, chromatin compaction, and transcription [22].
In this study we compared epigenetic alterations between
DIPG and GBM with respect to patient age and tumor
geographical location using archival formalin-fixed paraffin-
embedded material to gain a better understanding of epi-
genetic alterations specific to DIPG.
Materials and methods
Ethics statement
Human brain tumor samples and normal control tissue
were obtained at biopsy or autopsy at Johns Hopkins
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Hospital Department of Pathology, Children’s National
Medical Center and National Institutes of Health Center
for Cancer Research after Institutional Review Board ap-
proval or exemption. The research ethics committee
waived the requirement for informed consent for retro-
spective samples and no informed consent was obtained.
The patient data was de-identified prior to inclusion in
this study.
Human tissue microarray
DIPG tumor samples were obtained from tissue microar-
rays created at the National Institutes of Health from
rapid autopsy tissue for a total of 24 patients (3 to 15 years
of age, with a median age of 7) with each patient having
1–3 representative cores on the array and scored. Tumor
samples varied in size with a maximum width of 0.4 cm
and maximum length of 1.8 cm. Clinical and pathologic
features of this group have been previously published
(Additional file 1: Table S1) [1]. The subjects were anon-
ymized as part of the study approval and thus therapeutic
data was not collected. Tissue microarrays containing 64
adult GBM (22 to 86 years of age, with median age of 55)
and 36 pediatric GBM (less than 1year old to 21 years of
age, with median age of 13) were used as a comparison
group. Adult and pediatric GBM arrays were created by
the Johns Hopkins microarray core facility and have been
previously characterized (core diameter 0.6 mm) [23].
Samples with two or more scorable cores were included in
our dataset. Cores/samples were excluded from scoring
and data analysis if the sample was absent, degraded, or
no tumor present. Eight single cores from the GBM arrays
and one sample from the DIPG arrays were normal brain
and used as controls (i.e. the same normal brain samples
from patients were used for comparison between the dif-
ferent IHC stains). Only one normal brain was confirmed
to be from the pediatric age group.
Immunohistochemistry and scoring
The mouse monoclonal anti-Histone H3 (tri methyl K27)
antibody ChIP grade (Abcam, Cat# ab6002, Cambridge,
MA) was used at 1:1600 dilution. The antibody was incu-
bated overnight at 4°C. For H3K9me3 detection, rabbit
polyclonal anti-Histone H3 (tri methyl K9) antibody ChIP
Grade (Abcam, Cat# ab8898, Cambridge, MA) was used
at 1:8000 and incubated overnight at 4°C. Secondary
antibodies used were anti-rabbit (PV6119) or anti-mouse
(PV6114) from Novocastra PowerVision Poly-HR IHC
Detection System. Prostate tissue with characteristic stain-
ing patterns for H3K27me3 and H3K9me3 were used as
positive/negative control, and characteristic vessel wall
staining was used as an internal control for H3K27me3
staining. Once antibody concentration had been optimized
with prostate tissue, tissue microarrays were stained. 5hmC
detection was completed using the rabbit polyclonal
5-hmC specific antibody (Active Motif, Cat# 39769,
Carlsbad, CA) at a 1:20,000 dilution for 1 hour at room
temperature. The mouse monoclonal 5-methylcytosine
specific antibody (Calbiochem, EMD Chemicals Inc., Cat#
NA81-50UG, San Diego, CA) at a 1:2000 dilution incu-
bated for 1 hour at room temperature was used for 5mC
detection. After immunohistochemical staining, all tissue
arrays were counterstained with hematoxylin.
HEK293 cells transfected with expression vectors coding
for TET2 or control vectors were used as a standard in-
ternal control for all immunolabeling experiments for
5hmC as described previously [20]. HEK293 cells show
very low baseline levels of 5hmC. Overexpression of TET2
increases 5hmC levels resulting in detectable immunoreac-
tivity. The consistency of immunolabeling is documented
in Additional file 2: Figure S1 showing 5hmC staining
from 3 independent experiments. Control HEK293 cells
never show immunoreactivity, whereas TET2 trans-
fected cells consistently show 5hmC labeling. For 5mC
staining the same control slides were used.
Immunoreactivity was assessed by a neuropathologist
(FJR) using H-scores (H) (0–200) which were obtained
by multiplying intensity of stain (0: no stain, 1: weak
stain, 2: strong stain) by percentage (0–100) of neoplas-
tic cells showing the staining intensity [21]. Since most
normal terminally differentiated cells show high 5hmC
levels, all H-scores were internally normalized to the
staining intensities in the non-neoplastic cells. Every
case therefore served as its own internal control which
greatly reduced inconsistencies due to inadequate tissue
fixation.
mRNA expression profiling
Tissue mRNA expression profiling of 6 DIPG tissue sam-
ples and adjacent normal sections [4] were reanalyzed for
relative TET expression using Partek Genomics Suite v6.6
(Partek Incorporated, St. Louis, MO). Two of these sam-
ples are also represented in the TMA. Expression values
were extracted from Partek and graphed using Prism
Graph-Pad software (San Diego CA). All of the six speci-
mens used for this study had the H3.3K27M mutation.
Statistical analysis
Statistical analysis was completed using Graph-Pad Prism
6 software (Graph-Pad Software, La Jolla, CA). The non-
parametric Kruskal-Wallis one way analysis of variance
(ANOVA) test was used to identify differences between all
tumor subtype’s H-score medians. The Mann–Whitney test
was used to analyze differences by rank sum of H scores
between two tumor subtypes.
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Results
H3K27me3 levels are lower in DIPG compared to adult
and pediatric extrapontine GBM
H3K27me3 nuclear immunoreactivity was present in all
samples, and was particularly strong in non-neoplastic brain,
including neurons, glial and endothelial cells (Figure 1).
Decreased H3K27me3, defined as a H-score < 100, was
present in 37/116 (32%) scorable tumors, particularly in
DIPG 17/24 (71%) followed by pediatric 8/30(27%) and
adult GBM 12/62(19%). H3K27me3 median H-score
was significantly lower for DIPG (H = 80) compared to
pediatric GBM (H = 138) (p <0.01, Mann–Whitney Test),
adult GBM (H = 160) (p < 0.0001), and normal brain
(H-score 200) (p < 0.0001) tissue (Figure 2). A significant
difference was also noted in immunoreactivity between
control and adult GBM (p < 0.0001) and also control and
pediatric GBM (p < 0.0001). No difference was noted be-
tween adult and pediatric GBM immunoreactivity for
H3K27me3 (p > 0.05). Conversely, H3K9me3 immuno-
reactivity was relatively preserved in DIPG (H = 180)
and not significantly different from extrapontine GBM
(adult GBM H = 140, pediatric GBM H = 170, p > 0.05,
Kruskal-Wallis test of multiple comparisons). A significant
difference was noted between tumor groups and nor-
mal brain (H = 200, p < 0.05, Kruskal-Wallis test of mul-
tiple comparisons) explaining the Kruskal-Wallis ANOVA
p < 0.0001 (Figure 3).
DIPGs have increased 5hmC and decreased 5mC
compared with extrapontine GBM
Because alterations in DNA methylation levels represent
an important feature of DIPG, we next studied 5mC and
5hmC levels in a total of 94 scorable tumors from 3 tis-
sue microarrays (Figure 1). 5hmC immunoreactivity was
significantly higher for DIPG (H = 190) compared to
pediatric GBM (H = 110) (p < 0.0001) and adult GBM
(H = 100) (p < 0.0001). No significant difference in H-
scores was noted between DIPG tissue and normal brain
(H = 200) (p = 0.23). There was no significant difference
in 5hmC H-score between adult and pediatric GBM (p =
0.18) tissue (Figure 4). Conversely, 5mC was signifi-
cantly lower in DIPGs (H = 120) compared to pediatric
GBM (H= 170) (p < 0.001), adult GBM (H= 170) (p < 0.01),
and normal brain (H = 190) (p < 0.01). No significant dif-
ference in H-scores was noted between adult and pediatric
GBM (p = 0.61) tissue for 5mC (Figure 5).
Figure 1 Differential H3K27me3, 5mC and 5hmC immunoreactivity in DIPG and extrapontine GBM. Representative micrographs (400×) of
immunoreactivity for Histone 3 Lysine 27 trimethylation (H3K27me3), 5-methylcytosine (5mC), and 5-hydroxymethylcytosine (5hmC) in control
brain, pediatric glioblastoma (pGBM), adult glioblastoma (aGBM), and diffuse intrinsic pontine glioma (DIPG).
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DIPGs have increased mRNA expression of TET1 and TET3
relative to normal brain
Comparative analysis of DIPG tumor tissue and non-
neoplastic brain sections showed increased TET1 and
TET3 mRNA expression in tumor relative to patient
matched brain (as expressed in fold change). TET2 ex-
pression was not increased relative to normal brain
(Figure 6).
Discussion
We determined by IHC relative levels of H3K27me3,
5mC, and 5hmC in DIPG, pediatric GBM, and adult
GBM tissue. Our data are consistent with previously re-
ported low levels of H3K27me3 due to the H3K27M
mutation in the majority of DIPG. H3K9me3 in DIPG
was not significantly different from H3K9me3 immuno-
reactivity in extrapontine GBM and unlikely to be play-
ing a role in the tumorigenicity of DIPG. Surprisingly,
5hmC immunoreactivity was significantly elevated in
DIPG, in contrast to 5mC, suggesting that imbalance be-
tween 5hmC and 5mC plays a global role in the biology
of DIPG. In general, high levels of 5hmC have been
shown to be a feature of terminally differentiated cells
[20]. In numerous solid tumors including carcinoma of
the breast, prostate, colon, melanoma, and gliomas,
5hmC levels appear to be greatly reduced in neoplastic
cells [20]. Our group has previously shown that in adult
GBM and anaplastic astrocytoma high levels of 5hmC
Figure 2 H3K27me3 is decreased in DIPG. H-scores for Histone 3 Lysine 27 trimethylation (H3K27me3) immunoreactivity in normal brain
(Control), adult glioblastoma (aGBM), pediatric glioblastoma (pGBM), and diffuse intrinsic pontine glioma (DIPG) tissue (p < 0.0001, Kruskal-Wallis
ANOVA Test) (a). H3K27me3 median H-score was significantly lower for DIPGs compared to pediatric GBM (p < 0.01, Mann–Whitney Test), adult
GBM (p < 0.0001), and normal brain (p < 0.0001) tissue. A significant difference was also noted in immunoreactivity between control and adult
GBM (p < 0.0001) and also control and pediatric GBM (p < 0.0001). No difference was noted between adult and pediatric GBM immunoreactivity
for H3K27me3 (p > 0.05). Number of samples per group and median H-scores are specified in b.
Figure 3 H3K9me3 immunoreactivity is no different in DIPG, adult GBM, and pediatric GBM. H-scores for Histone 3 Lysine 9 trimethylation
(H3K9me3) immunoreactivity in normal brain (Control), adult glioblastoma (aGBM), pediatric glioblastoma (pGBM), and diffuse intrinsic pontine
glioma (DIPG) tissue (p < 0.0001, Kruskal-Wallis ANOVA Test) (a). H3K9me3 immunoreactivity was relatively preserved in DIPG and not significantly
different from extrapontine GBM (adult GBM p > 0.05, pediatric GBM p > 0.05, Kruskal-Wallis test of multiple comparisons). A significant difference
was noted between tumor groups and normal brain (p < 0.05, Kruskal-Wallis test of multiple comparisons). Number of samples per group and
median H-scores are specified in b.
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are associated with a less aggressive phenotype [21].
However, the global DNA hypomethylation that occurs
in DIPG in conjunction with relatively increased 5hmC
may represent signs of a novel global epigenetic dysregu-
lation state distinct from that of adult high grade glioma.
The elevation of 5hmC in DIPG must be considered in
the context of global loss of 5mC in these tumors. The
striking imbalance between 5hmC and 5mC in DIPG
may be another sign of the marked epigenetic dysregula-
tion which underlies these aggressive tumors.
A limitation of our study is the relative lack of clinical
data available for the patient samples. We do not know
which, if any, chemotherapeutic agents patients have
been treated with and whether they have received radi-
ation. Our findings may be affected by prior treatment
but the internal consistency of our findings within tumor
groups supports their significance. The underlying cause
for the shift in balance towards increased 5hmC expres-
sion relative to 5mC in DIPG compared to normal brain
and extrapontine GBM is unclear. However, one possibility
is altered activity of TETs. Preliminary evaluation of
TET mRNA expression shows elevation of TET1 and
TET3 in DIPG compared to control brain. In other can-
cer types, TET is mutated and inactivated, leading to
globally decreased 5hmC and increased DNA methyla-
tion [17]. In contrast, a possible result of the loss of glo-
bal DNA methylation could be deposition of the 5hmC
intermediary and epigenetic imbalance.
During differentiation, global levels of 5hmC and
H3K27me3 are tightly co-regulated and in most solid
tumors both marks are concordantly reduced [24]. The
data presented here suggests that DIPGs have a unique
epigenetic fingerprint featuring high 5hmC and loss of
H3K27me3. This epigenetic constellation may contribute
to DIPG tumor initiation and maintenance. The alteration
in H3.3 which inactivates EZH2 and global DNA hypo-
methylation suggests that two regulatory pathways that
communicate to maintain normal brain development
are altered in this tumor type, leading to an unopposed
active transcriptional state (Figure 7). Elevated 5hmC
Figure 4 5hmC is increased in DIPG. H-scores for 5-hydroxymethylcytosine (5hmC) immunoreactivity in normal brain (control), adult glioblastoma
(aGBM), pediatric glioblastoma (pGBM), and diffuse intrinsic pontine glioma (DIPG) tissue (p < 0.0001, Kruskal-Wallis ANOVA Test) (a). Number of
samples per group and median H-scores are specified in b.
Figure 5 5mC is decreased in DIPG. H-scores for 5-methylcytosine (5mC) immunoreactivity in normal brain (Control), adult glioblastoma (aGBM),
pediatric glioblastoma (pGBM), and diffuse intrinsic pontine glioma (DIPG) tissue (p < 0.0024, Kruskal-Wallis ANOVA Test). (a). Number of samples
per group and median H-scores are specified in b.
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and depressed H3K27me3 in normal brain development
are associated with neural differentiation and affect neural
migration through inhibition of EZH2 (part of the PRC2
complex) [20,18]. We hypothesize that migration is aber-
rant in DIPG since EZH2 is no longer able to function at
Lysine 27 in Histone 3.3. Elevated 5hmC is found in differ-
entiating cells and usually in conjunction with H3K27me3
loss. There is a possibility that the Histone 3 and cytosine
methylation pathways cross-talk and co-regulate each
other. However, in DIPG, aberrant TET enzyme expres-
sion may result in loss of 5mC and increased 5hmC. This
may lead to aberrant PRC2 sequestration from primary
targets, a transcriptionally active state, and tumorigenicity.
Histone and cytosine methylation dysregulation is
unique to DIPG. When neither pathway is able to func-
tion in its regulatory role in neural development, DIPG
develops. This epigenetic imbalance may underlie DIPG
tumor formation and resistance to treatment. Our work
supports recent findings indicating that H3K27me3 loss,
through the dominant negative H3K27M mutation, is
associated with DNA hypomethylation and an increase
in transcriptionally upregulated genes. This suggests that
there is crosstalk between histone methylation pathways
and DNA methylation pathways leading to changes in
transcriptional activity [10].
Conclusions
The H3.3 Lysine 27 is a critical site for the deposition of
an inhibitory epigenetic mark and is mutated in the ma-
jority of DIPG, suggesting that targeting epigenetics
could be one therapeutic approach for this highly ag-
gressive pediatric tumor. Understanding the epigenetic
landscape of DIPG opens up the opportunity for epigen-
etic modifiers, which could potentially shift the active
genome of this deadly tumor into a silent and regulated
state. The role of epigenetic modifiers such as methyla-
tion inhibitors and histone deacetylase inhibitors [7] in
treating DIPG needs to be reevaluated as the epigenetic
mechanisms of DIPG are better understood.
Additional files
Additional file 1: Table S1. DIPG specimen demographic and
histological characteristics adapted from Ballester et al. (-) data not available.
Additional file 2: Figure S1. HEK293 cells are positive controls for 5mC
IHC and negative controls for 5hmC. TET overexpressed HEK293 cells
function as positive controls for 5hmC IHC. Figure 1a is a representative
image of IHC staining of HEK293 cells for 5mC (positive control).
Figure 1b shows representative images from three different rounds of
staining for 5hmC with HEK293 cells overexpressed for TET2 stained for
5hmC on the right (positive control) and control transfected HEK293 cells
not showing any immunoreactivity for 5hmC on the left (negative control).
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glioblastoma; α-KG: Alpha-ketoglutarate; BER: Base excision repair;
DIPG: Diffuse intrinsic pontine glioma; DNMT: DNA methyltransferase;
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Figure 6 TET1 and TET3 expression are increased in DIPG
tumors relative to normal brain. mRNA expression profiling of
H3F3A mutant DIPG tumor tissue shows relative increased
expression of TET1 and TET3, but not TET2, in tumor relative to
adjacent non-neoplastic brain control.
Figure 7 Overproduction of 5hmC and disruption of histone
methylation may contribute to DIPG tumorigenesis. Normal
neural development is controlled by histone and DNA methylation
executed by enhancer of zeste homologue 2 (EZH2) methyltransferase,
DNA methyltransferase (DNMT), Ten Eleven Translocation (TET),
Thymine-DNA glycosylase (TDG), and base excision repair (BER).
Dysregulation of the epigenome by H3F3A mutation/EZH2 inhibition
and corresponding overproduction of 5hmC by TET in DIPG may
promote DIPG tumorigenicity.
Ahsan et al. Acta Neuropathologica Communications 2014, 2:59 Page 7 of 9
http://www.actaneurocomms.org/content/2/1/59
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SA participated in design and coordination of study, scored and collected
data, performed the statistical analysis, and drafted the manuscript. ER
participated in design and coordination of the study and manuscript writing.
Also provided materials necessary for the study. MH optimized and
performed immunohistochemistry and participated in the design and
coordination of the study. AV optimized and performed
immunohistochemistry. KW participated in design and coordination of the
study. MQ participated in design and coordination of the study. LB
participated in design and coordination of the study. JN participated in
design and coordination of the study, collected data, and performed
statistical analysis. CE conceived of the study and participated in design and
coordination of the study. FR conceived of the study and participated in
design and coordination of the study. All authors critically read and
approved the final manuscript.
Acknowledgements
This work was supported in part by the T32 CA60441 NIH/NCI Grant: Lab
Research Training in Pediatric Oncology-Hematology (SA), the Children’s
Cancer Foundation Inc. (CGE, FJR), Childhood Brain Tumor Foundation (FJR),
St. Baldrick’s Foundation (EHR), and a CureSearch Brain Tumor Young
Investigator Grant (EHR). The authors also thank Jessica Hicks of the
Immunohistochemical Core for technical assistance.
Author details
1Johns Hopkins Division of Pediatric Oncology, Baltimore 21218, MD, USA.
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, 1800
Orleans St, 21287 Baltimore, MD, USA. 3National Institutes of Health, National
Cancer Institute, Pediatric Oncology Branch, Bethesda, MD, USA. 4National
Institutes of Health, National Cancer Institute, Laboratory of Pathology,
Bethesda, MD, USA. 5Center for Genetic Medicine, Children’s National
Medical Center, 111 Michigan Ave NW, 20010 Washington, DC, USA.
6Department of Integrative Systems Biology, George Washington University
School of Medicine and Health Sciences, Washington 20010, DC, USA.
7Division of Neuropathology, Johns Hopkins University, Baltimore 21218, MD,
USA.
Received: 18 April 2014 Accepted: 26 May 2014
Published: 3 June 2014
References
1. Ballester L, Wang Z, Shandilya S, Miettinen M, Burger P, Eberhart C,
Rodriguez F, Raabe E, Nazarian J, Warren K, Quezado M: Morphologic
characteristics and immunohistochemical profile of diffuse intrinsic
pontine gliomas. Am J Surg Pathol 2013, 37(9):1357–1364. doi:10.1097/
PAS.0b013e318294e817.
2. Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, Olson JM,
Geyer JR, Chi SN, Da Silva NS, Onar-Thomas A, Baker JN, Gajjar A, Ellison DW,
Baker SJ: Genome-wide analyses identify recurrent amplifications of
receptor tyrosine kinases and cell-cycle regulatory genes in diffuse
intrinsic pontine glioma. J Clin Oncol 2011, 29(30):3999–4006. doi:10.1200/
JCO.2011.35.5677.
3. Paugh BS, Zhu X, Qu C, Endersby R, Diaz AK, Zhang J, Bax DA, Carvalho D,
Reis RM, Onar-Thomas A, Broniscer A, Wetmore C, Zhang J, Jones C, Ellison DW,
Baker SJ: Novel oncogenic PDGFRA mutations in pediatric high-grade
gliomas. Cancer Res 2013, 73(20):6219–6229. doi:10.1158/0008-5472.
CAN-13-1491.
4. Saratsis AM, Kambhampati M, Snyder K, Yadavilli S, Devaney JM, Harmon B,
Hall J, Raabe EH, An P, Weingart M, Rood BR, Magge SN, Macdonald TJ,
Packer RJ, Nazarian J: Comparative multidimensional molecular analyses
of pediatric diffuse intrinsic pontine glioma reveals distinct molecular
subtypes. Acta Neuropathol 2013. doi:10.1007/s00401-013-1218-2.
5. Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M,
Morrison A, Lewis P, Bouffet E, Bartels U, Zuccaro J, Agnihotri S, Ryall S,
Barszczyk M, Chornenkyy Y, Bourgey M, Bourque G, Montpetit A, Cordero F,
Castelo-Branco P, Mangerel J, Tabori U, Ho KC, Huang A, Taylor KR, Mackay A,
Bendel AE, Nazarian J, Fangusaro JR, Karajannis MA, et al: Genomic analysis of
diffuse intrinsic pontine gliomas identifies three molecular subgroups and
recurrent activating ACVR1 mutations. Nat Genet 2014, doi:10.1038/ng.2936.
6. Taylor KR, Mackay A, Truffaux N, Butterfield YS, Morozova O, Philippe C,
Castel D, Grasso CS, Vinci M, Carvalho D, Carcaboso AM, De Torres C,
Cruz O, Mora J, Entz-Werle N, Ingram WJ, Monje M, Hargrave D, Bullock AN,
Puget S, Yip S, Jones C, Grill J: Recurrent activating ACVR1 mutations in
diffuse intrinsic pontine glioma. Nat Genet 2014. doi:10.1038/ng.2925.
7. Dewoskin V, Million R: The epigenetics pipeline. Nat Rev Drug Discov 2013,
12(9):661–662. doi:10.1038/nrd4091.
8. Schwartzentruber J, Korshunov A, Liu X-Y, Jones D, Pfaff E, Jacob K, Sturm D,
Fontebasso A, Quang D-AK, Tönjes M, Hovestadt V, Albrecht S, Kool M,
Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel J,
Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann M,
Scheurlen W, Pekrun A, Frühwald M, et al: Driver mutations in histone H3.3
and chromatin remodelling genes in paediatric glioblastoma. Nature 2012,
482(7384):226–231. doi:10.1038/nature10833.
9. Sturm D, Witt H, Hovestadt V, Khuong-Quang D-A, Jones D, Konermann C,
Pfaff E, Tönjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M,
Hielscher T, Liu X-Y, Fontebasso A, Ryzhova M, Albrecht S, Jacob K, Wolter M,
Ebinger M, Schuhmann M, van Meter T, Frühwald M, Hauch H, Pekrun A,
Radlwimmer B, Niehues T, von Komorowski G, et al: Hotspot mutations in
H3F3A and IDH1 define distinct epigenetic and biological subgroups of
glioblastoma. Cancer Cell 2012, 22(4):425–437. doi:10.1016/j.ccr.2012.08.024.
10. Bender S, Tang Y, Lindroth A, Hovestadt V, Jones D, Kool M, Zapatka M,
Northcott P, Sturm D, Wang W, Radlwimmer B, Højfeldt J, Truffaux N, Castel D,
Schubert S, Ryzhova M, Seker-Cin H, Gronych J, Johann P, Stark S, Meyer J,
Milde T, Schuhmann M, Ebinger M, Monoranu C-M, Ponnuswami A, Chen S,
Jones C, Witt O, Collins V, et al: Reduced H3K27me3 and DNA Hypomethylation
Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade
Gliomas. Cancer Cell 2013, 24(5):660–672. doi:10.1016/j.ccr.2013.10.006.
11. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L,
Huether R, Parker M, Zhang J, Gajjar A, Dyer MA, Mullighan CG, Gilbertson RJ,
Mardis ER, Wilson RK, Downing JR, Ellison DW, Zhang J, Baker SJ, St. Jude
Children’s Research Hospital-Washington University Pediatric Cancer Genome
P: Somatic histone H3 alterations in pediatric diffuse intrinsic pontine
gliomas and non-brainstem glioblastomas. Nat Genet 2012, 44(3):251–253.
doi:10.1038/ng.1102.
12. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM,
Bouffet E, Bartels U, Albrecht S, Schwartzentruber J, Letourneau L, Bourgey M,
Bourque G, Montpetit A, Bourret G, Lepage P, Fleming A, Lichter P, Kool M,
von Deimling A, Sturm D, Korshunov A, Faury D, Jones DT, Majewski J,
Pfister SM, Jabado N, Hawkins C: K27M mutation in histone H3.3 defines
clinically and biologically distinct subgroups of pediatric diffuse
intrinsic pontine gliomas. Acta Neuropathol 2012, 124(3):439–447.
doi:10.1007/s00401-012-0998-0.
13. Lewis P, Müller M, Koletsky M, Cordero F, Lin S, Banaszynski L, Garcia B, Muir T,
Becher O, Allis C: Inhibition of PRC2 activity by a gain-of-function H3
mutation found in pediatric glioblastoma. Science (New York, NY) 2013,
340(6134):857–861. doi:10.1126/science.1232245.
14. Sparmann A, van Lohuizen M: Polycomb silencers control cell fate,
development and cancer. Nat Rev Cancer 2006, 6(11):846–856.
doi:10.1038/nrc1991.
15. Reddington J, Perricone S, Nestor C, Reichmann J, Youngson N, Suzuki M,
Reinhardt D, Dunican D, Prendergast J, Mjoseng H, Ramsahoye B, Whitelaw E,
Greally J, Adams I, Bickmore W, Meehan R: Redistribution of H3K27me3 upon
DNA hypomethylation results in de-repression of Polycomb target genes.
Genome Biol 2013, 14(3). doi:10.1186/gb-2013-14-3-r25.
16. Pfeifer G, Kadam S, Jin S-G: 5-hydroxymethylcytosine and its potential
roles in development and cancer. Epigenetics Chromatin 2013, 6(1):10.
doi:10.1186/1756-8935-6-10.
17. Sun W, Guan M, Li X: 5-hydroxymethylcytosine-mediated DNA
demethylation in stem cells and development. Stem Cells Dev 2014.
doi:10.1089/scd.2013.0428.
18. Hahn M, Qiu R, Wu X, Li A, Zhang H, Wang J, Jui J, Jin S-G, Jiang Y, Pfeifer G,
Lu Q: Dynamics of 5-hydroxymethylcytosine and chromatin marks in
Mammalian neurogenesis. Cell Rep 2013, 3(2):291–300. doi:10.1016/j.
celrep.2013.01.011.
19. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y:
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and
5-carboxylcytosine. Science 2011, 333(6047):1300–1303. doi:10.1126/
science.1210597.
Ahsan et al. Acta Neuropathologica Communications 2014, 2:59 Page 8 of 9
http://www.actaneurocomms.org/content/2/1/59
20. Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A,
Argani P, Iacobuzio-Donahue C, Nelson WG, Netto GJ, De Marzo AM,
Yegnasubramanian S: Global 5-hydroxymethylcytosine content is
significantly reduced in tissue stem/progenitor cell compartments
and in human cancers. Oncotarget 2011, 2(8):627–637.
21. Orr B, Haffner M, Nelson W, Yegnasubramanian S, Eberhart C: Decreased
5-hydroxymethylcytosine is associated with neural progenitor phenotype
in normal brain and shorter survival in malignant glioma. PLoS One
2012, 7(7). doi:10.1371/journal.pone.0041036.
22. Venneti S, Garimella MT, Sullivan LM, Martinez D, Huse JT, Heguy A, Santi M,
Thompson CB, Judkins AR: Evaluation of histone 3 lysine 27
trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric
glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A
K27M mutant glioblastomas. Brain Pathol 2013, 23(5):558–564.
doi:10.1111/bpa.12042.
23. Odia Y, Orr BA, Bell WR, Eberhart CG, Rodriguez FJ: cMYC expression in
infiltrating gliomas: associations with IDH1 mutations, clinicopathologic
features and outcome. J Neurooncol 2013, 115(2):249–259. doi:10.1007/
s11060-013-1221-4.
24. Haffner M, Pellakuru L, Ghosh S, Lotan T, Nelson W, De Marzo A,
Yegnasubramanian S: Tight correlation of 5-hydroxymethylcytosine and
Polycomb marks in health and disease. Cell Cycle 2013, 12(12):1835–1841.
doi:10.4161/cc.25010.
doi:10.1186/2051-5960-2-59
Cite this article as: Ahsan et al.: Increased 5-hydroxymethylcytosine and
decreased 5-methylcytosine are indicators of global epigenetic
dysregulation in diffuse intrinsic pontine glioma. Acta Neuropathologica
Communications 2014 2:59.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ahsan et al. Acta Neuropathologica Communications 2014, 2:59 Page 9 of 9
http://www.actaneurocomms.org/content/2/1/59
